Puigvehí, Marc
Londoño, María-Carlota
Torras, Xavier
Lorente, Sara
Vergara, Mercedes
Morillas, Rosa Maria
Masnou, Helena
Serrano, Trinidad
Miquel, Mireia
Gallego, Adolfo
Lens, Sabela
Carrión, Jose Antonio http://orcid.org/0000-0001-7191-6081
Article History
Received: 23 May 2019
Accepted: 25 August 2019
First Online: 6 September 2019
Compliance with ethical standards
:
: MCL: advisory fees from Janssen, MSD, AbbVie, Gilead and BMS. XT: Speaker fees from AbbVie, MSD and Gilead; advisory board for Gilead and MSD. SL: lecture fees from Gilead, AbbVie, Merck, BMS and Janssen. MV: lecture fees from Gilead Sciences, AbbVie and MSD. RMM: Speaker fees from Gilead, AbbVie, Merck, BMS, Janssen and Intercept. TS: Speaker fees from Gilead, AbbVie, and MSD. MM: lecture fees from Gilead, AbbVie and Merck. SL: speaker and consultant fees from Gilead, AbbVie and Janssen. JAC: lecture fees from Bristol Myers Squibb, Gilead Sciences, Roche/Genentech and Jansen; the remaining authors declare no conflict of interest.